TAFIa inhibitors in the treatment of thrombosis

Current Opinion in Drug Discovery and Development

Volumn 11, Issue 4, 2008, Pages 480-486

  Bunnage, M E ^a   Owen, D R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Carboxypeptidase; Carboxypeptidase U; Inhibitor; TAFIa; Thrombosis; Zinc metalloprotease

Indexed keywords

2 AMINOPYRIDINE DERIVATIVE; 3 (2 GUANIDINOETHYLTHIO) 2 (MERCAPTOMETHYL)PROPIONIC ACID; ACTIVATED THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; ALTEPLASE; AZD 9684; BX 528; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; EF 6265; ENALAPRIL; FIBRIN; IMIDAZOLE DERIVATIVE; PHOSPHINIC ACID DERIVATIVE; SAR 104772; SQ 24798; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; UK 396082; ZINC;

CLINICAL TRIAL; DISEASE MODEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TARGETING; ENZYME ACTIVITY; FIBRINOLYSIS; HEMOSTASIS; HUMAN; IC 50; KIDNEY CLEARANCE; MEDICAL LITERATURE; NONHUMAN; PATENT; PROTEIN FUNCTION; PUBLICATION; REVIEW; THROMBOSIS;

ANIMALS; CARBOXYPEPTIDASE U; DRUG DESIGN; ENZYME ACTIVATION; FIBRINOLYTIC AGENTS; HUMANS; IMIDAZOLES; MOLECULAR STRUCTURE; PHOSPHINIC ACIDS; PROTEASE INHIBITORS; SULFHYDRYL COMPOUNDS; THROMBOSIS;

EID: 46749103227     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Leurs J, Hendriks D: Carboxypeptidase U (TAFIa): A metallocarboxypeptidase with a distinct role in hemostasis and a possible risk factor for thrombotic disease. Thromb Haemost (2005) 94(3):471-487.
2. Nesheim M, Bajzar L: The discovery of TAFI. J Thromb Haemost (2005) 3(10):2139-2146. •• Provides a definitive review of the research into TAFI by one of the discoverers of the zymogen.
3. Hass CM, Venkatakrishnan R, Ryan CA: Homologous inhibitors from potato tubers of serine endopeptidases and metallocarboxypeptidases. Proc Natl Acad Sci USA (1976) 73(6):1941-1944.
4. Bajzar L, Nesheim ME, Tracy PB: The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood (1996) 88(6):2093-2100.
5. Ondetti MA, Rubin B, Cushman DW: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science (1977) 196(4288):441-444.
6. Lee KJ, Joo KC, Kim E-J, Lee M, Kim DH: A new type of carboxypeptidase A inhibitors designed using an imidazole as a zinc coordinating ligand. Bioorg Med Chem (1997) 5(10):1989-1998. • Provides an early and rare example of the use of an imidazole as a ligand for coordinating zinc in a carboxypeptidase inhibitor.
7. Barrow JC, Nantermet PG, Stauffer SR, Ngo PL, Steinbeiser MA, Mao SS, Carroll SS, Bailey C, Colussi D, Bosserman M, Burlein C et al: Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J Med Chem (2003) 46(25):5294-5297.
8. Nantermet PG, Barrow JC, Lindsley SR, Young M, Mao SS, Carroll S, Bailey C, Bosserman M, Colussi D, McMasters DR, Vacca JP et al: Imidazole acetic acid TAFIa inhibitors: SAR studies centered around the basic P1' group. Bioorg Med Chem Lett (2004) 14(9):2141-2145.
9. Bunnage ME, Blagg J, Steele J, Owen DR, Allerton C, McElroy AB, Miller D, Ringer T, Butcher K, Beaumont K, Evans K et al: Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis. J Med Chem (2007) 50(24):6095-6103. •• Provides a full description of the program to convert a non-selective thiol lead into a selective, imidazole-based development candidate. This is a rare example of published phase I toleration data and human pharmacokinetic data in the research area of TAFI.
10. Islam I, Bryant J, May K, Mohan R, Yuan S, Kent L, Morser J, Zhao L, Vergona R, White K, Adler M et al: 3-Mercaptopropionic acids as efficacious inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg Med Chem Lett (2007) 17(5):1349-1354. • Provides the only published literature on the Berlex Biosciences thiol program. The research demonstrates how carboxypeptidase N selectivity was improved, and provides some evidence for preclinical efficacy and safety.
11. Polla MO, Tottie L, Nordén C, Linschoten M, Müsil D, Trumpp-Kallmeyer S, Aukrust IR, Ringom R, Holm KH, Neset SM, Sandberg M et al: Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem (2004) 12(5):1151-1175.
12. DailyDrugNews.com: AstraZeneca updates status of development portfolio. Prous Science Daily Essentials (2006) June 13.
13. AstraZeneca plc: First quarter results 2007. Press Release (2007) April 23.
14. Björkman JE, Abrahamsson TI, Nerme VK, Mattsson CJ: Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. Thromb Res (2005) 116(6):519-524.
15. Wang YX, Zhao L, Nagashima M, Vincelette J, Sukovich D, Li W, Subramanyam B, Yuan S, Emayan K, Islam I, Hrvatin P et al: A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) - Part I: Pharmacological characterization. Thromb Haemost (2007) 97(1):45-53.
16. Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K, Yuan S, Emayan K, Islam I, Hosoya J, Sullivan ME et al: A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - Part II: Enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost (2007) 97(1):54-61. •• Reports pharmacokinetic, efficacy and preclinical safety data for BRX-528 from Berlex Biosciences.
17. Emayan K, Yuan S, Islam I, Hrvatin PM, West C, Chang Z, Bryant J, Chu K, Sukovich D, Buckman BO: 3-Phosphinoylpropionic acid inhibitors of thrombin activatable fibrinolysis inhibitor (TAFI) 1: Design, synthesis and biological activity. 232nd American Chemical Society National Meeting, San Francisco, CA, USA (2006):MEDI 397.
18. Yuan S, Emayan K, Islam I, Hrvatin PM, West C, Chang Z, Bryant J, Chu K, Sukovich D, Morser J, Dole B et al: 3-Phosphinoylpropionic acid inhibitors of thrombin activatable fibrinolysis inhibitor (TAFI) 2: In vitro and in vivo evaluation. 232nd American Chemical Society National Meeting, San Francisco, CA, USA (2006):MEDI 398.
19. Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S et al: Enhancement of fibrinolysis by EF-6265 [(S)-7-amino-2-[[[(R)-2- methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther (2004) 309(2):607-615. •• Provides evidence for the renal protective properties of EF-6265, the TAFIa inhibitor that is being researched by Meiji Seika Kaisha.
20. Ravindranath TM, Goto M, Iqbal O, Florian-Kujawski M, Hoppensteadt D, Hammadeh R, Sayeed MM, Fareed J: Plasma thrombin activatable fibrinolysis inhibitor and tissue factor pathway inhibitor changes following sepsis. Clin Appl Thromb Hemost (2007) 13(4):362-368.
21. Gao H, Xu Y, Xu C: Thrombin-activatable fibrinolysis inhibitor and deep vein thrombosis. Xueshuan Yu Zhixuexue (2006) 12(6):276-278.
22. Gursoy T, Tekinalp G, Yurdakok M, Ozcebe O, Korkmaz A, Gurgey A: Thrombin activatable fibrinolysis inhibitor activity, thrombin-antithrombin complex and D-dimer levels in preterm neonates with early respiratory distress syndrome. Am J Hematol (2007) 83(1):50-53.
23. Rooth E, Wallen H, Antovic A, von Arbin M, Kaponides G, Wahlgren N, Blombaeck M, Antovic J: Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis (2007) 18(4):365-370.
24. Bruno NE, Yano Y, Takei Y, Gabazza EC, Qin L, Nagashima M, Morser J, D'Alessandro-Gabazza CN, Taguchi O, Sumida Y: Protective role of thrombin activatable fibrinolysis inhibitor in obstructive nephropathy-associated tubulointerstitial fibrosis. J Thromb Haemost (2008) 6(1):139-146.
25. Özcan MA, Akar S, Alacacioǵlu I, Pişkin O, Yüksel F, Gürler O, Akkoç N, Demirkan F, Özsan GH, Özkan S, Önen F et al: Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease. Turkish J Med Sci (2007) 37(5):267-271.
26. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW et al: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol (2007) 82(11):1010-1012.
27. Rigla M, Wägner AM, Borrell M, Mateo J, Foncuberta J, de Leiva A, Ordóñez-Llanos J, Pérez A: Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metabolism (2006) 55(11):1437-1442.
28. Marx PF: Thrombin-activatable fibrinolysis inhibitor. Curr Med Chem (2004) 11(17):2335-2348.
29. Dusse LM, Cooper AJ, Lwaleed BA: Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia? Clin Chim Acta (2007) 378(1-2):1-6.
30. Gumus K, Kadayifcilar S, Eldem B, Ozcebe O: Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion. Retina (2007) 27(5):578-583.
31. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, de Franchis R, Vecchi M: Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol (2004) 99(10):1966-1970.
32. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster J-C, Busso N: Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost (2003) 1(12):2510-2515.
33. Bajzar L, Jain N, Wang P, Walker JB: Thrombin activatable fibrinolysis inhibitor: Not just an inhibitor of fibrinolysis. Crit Care Med (2004) 32(5 Suppl):S320-S324. •• Provides a full perspective on the potential for TAFIa inhibitors beyond thrombosis.
34. SANOFI-AVENTIS DEUTSCHLAND GMBH (Lindenschmidt A, Kallus C, Heitsch H, Grueneberg S, Szillat H): Imidazole derivatives as TAFIa inhibitors. US-20070129341 (2007).
35. SANOFI-AVENTIS (Wehner V, Kallus C, Heitsch H): Imidazole derivatives as inhibitors of TAFIa. WO-2007045339 (2007).
36. AVENTIS RESEARCH & TECHNOLOGIES (Kallus C, Heitsch H, Lindenschmidt A, Grueneberg S): Imidazole derivatives used as TAFIa inhibitors. WO-2005105781 (2005).
37. PFIZER INC (Allerton CM, Blagg J, Bunnage ME, Steele J): Substituted imidazoles as TAFIa inhibitors. WO-02014285 (2002).
38. ASTRAZENECA AB (Linschoten M, Polla M): Potential inhibitors of carboxypeptidase U. WO-00066550 (2000).
39. Linschoten M, Polla M: Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors. US-20060079484 (2006).
40. ASTRAZENECA AB (Polla M): Preparation of phosphoryl propanoic acid derivatives as inhibitors of carboxypeptidase U. WO-03027128 (2003).
41. MEIJI SEIKA KAISHA LTD (Fushihara K, Kikuchi C, Matsushima T, Kanemoto K, Satoh E, Yamamoto T, Suzuki K): Phosphonic acid derivatives having carboxypeptidase B inhibitory activity. WO-01019836 (2001).
42. BAYER SCHERING PHARMA AG/MIE UNIVERSITY SCHOOL OF MEDICINE (Gabazza EC, Taguchi O, Fujimoto HM): TAFI inhibitors and their use to treat pulmonary fibrosis. WO-06041808 (2006).
43. ASTRAZENECA AB (Björquist P, Buchanan M, Campitelli M, Carroll A, Hyde E, Neve J, Polla M, Quinn R): Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase U is beneficial, novel anabaenopeptin derivatives and intermediates thereof. WO-05039617 (2005).